Tuberculosis Treatment Market By Drug Class (First Line Treatment, Second Line Treatment) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

This report on global tuberculosis treatment market studies various drug class. According to World Health Organization (WHO) approximately 49 million lives were saved from 2000-2015 through effective diagnosis and treatment, its end TB strategy aims to eradicate the global TB epidemic with 95% reduction in TB deaths, and to cut new cases by 90% from 2015 to 2035 and to ensure that patients are not burdened with huge expenses incurred due to TB. The drivers of the tuberculosis treatment market are rising prevalence of TB and MDR-TB, increasing public awareness regarding tuberculosis and immediate enrollment of patient on the treatment regimen. Promising pipeline to overcome the drug induced resistance comprises of Bedaquiline, OPC-67683, PA-824 and OFLOTUB etc.

For the purpose of this study, the various drug class of tuberculosis treatment studied include first line of treatment which is segmented as Isoniazid, Ethambutol, Pyrazinamide and Rifampin. The second line of treatment comprises of Ethionamide, Cycloserine, Para-amino salicylic acid and Kanamycin. The geographic segmentation of the global tuberculosis treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of, cross-sectional study by drug class and major countries.

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global tuberculosis treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global tuberculosis treatment market. The key players profiled in this report are Bayer Healthcare, Eli Lilly & Co., Labatec Pharma SA, Macleods Pharmaceuticals Pvt. Ltd., Mylan N.V., Novartis AG, Otsuka Novel Products GmbH, Patheon, Inc., Pfizer, Inc. and Sanofi S.A.

Tuberculosis Treatment Market

Based on drug class, the global tuberculosis treatment market is categorized into

  • First line treatment
    • Cytochrome P-450 inhibitor (Isoniazid)
    • Mycolic acid inhibitor (Ethambutol)
    • FAS I inhibitor (Pyrazinamide)
    • RNA polymerase inhibitor (Rifampin)
  • Second line treatment
    • Mycolic acid inhibitor (Ethionamide)
    • Peptidoglycans inhibitor (Cycloserine)
    • Folic acid inhibitor (Para-aminosalicylic acid)
    • 30S ribosomal inhibitor (Kanamycin)

Tuberculosis Treatment Market

United Nations in 2015 has adopted the sustainable development goals (SDGs) with one of its major target to eradicate tuberculosis, similarly the World Health Organization is claiming TB strategy class for 90% reduction in tuberculosis deaths and 80% reduction in TB incidence rate by 2030.  Rising public awareness regarding tuberculosis and its treatment regimen, and availability at low cost is fuelling the tuberculosis drug class segment growth. In 2016, first line treatment holds the largest market due to increasing number of new cases of TB, early TB screening resulting into large turnout of patients on first line treatment and government initiatives such as DOTS at the primary health centers to bring under its ambit patients with unmet medical needs. Second line treatment will register faster growth throughout the forecast period 2017-2025, due to factor such as rising prevalence of MDR-TB, according to World Health Organization in 2015 there were 480,000 new reported cases, lack of patient’s compliance to the prescribed first line treatment dosage regimen and rising incidences of hospital acquired infections. Overall, the tuberculosis drug market is highly competitive with presence of multiple players like Novartis AG, Bayer Healthcare, Labatec Pharma SA, Mylan N.V., Otsuka Novel Products GmbH, etc. specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the technological advancement in the drug formulation regarding the pharmacodynamics and pharmacokinetic aspects for better patient compliance and available at low cost.

For the purpose of this study, the global tuberculosis treatment market is categorized into:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Tuberculosis Treatment Market

North America will be the fastest growing market for tuberculosis treatment throughout the forecast period 2017-2025. According to the Centers for Disease Control and Prevention 9,421 TB cases were reported in 2014 i.e. rate of 2.96 cases per 100,000 persons, the market growth is mainly attributed to rising prevalence of tuberculosis, evolved reimbursement scenario, and developed healthcare infrastructure. According to the World Health Organization (WHO) in 2015, 32,000 patient’s death were reported in Europe, the tuberculosis treatment market growth is attributed to prevalence of MDR-TB in eastern European countries and supportive regulatory approval for tuberculosis treatment market. In base year 2016, Asia Pacific was observed as the leading market for tuberculosis treatment due to factors such as rising prevalence of tuberculosis, according to World Health Organization South East Asia has 4.8 million prevalent cases and 450,000 deaths in 2012, competitive market due to manufactures involved in production of tuberculosis treatment drugs, increasing disposable income in these regions and government and non-government initiatives such as DOTS to mitigate tuberculosis. However, factors such as developing health infrastructure, increasing awareness about tuberculosis treatment are going to fuel the rapid growth of tuberculosis treatment market in Latin America and Middle East and Africa region in the near future.   

Choose License Type
Published Date:  Jul 2017
Category:  Pharmaceuticals
Report ID:   58586
Report Format:   PDF
Pages:   120
Rating:    4.2 (50)
Connect With Us
+1-408-641-3282
24/7 Research Support